TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Brief Summary: This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients. In a cross-over design, patients will be randomized to receive either a single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated time on study is up to approximately 9 weeks.


Options:
A: Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5028442 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5028442; Assigned to Arm(s): 1
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Buspirone | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Buspirone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.


Options:
A: Arm Label: Investigational drug - Dose 1; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Investigational drug - Dose 2; Type: EXPERIMENTAL; Interventions: Drug: ACT-128800 | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ACT-128800; Assigned to Arm(s): Investigational drug - Dose 1, Investigational drug - Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis.


Options:
A: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
C: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled Cross-over Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Painful Diabetic Peripheral Neuropathy And Pain On Walking
Brief Summary: The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life.


Options:
A: Arm Label: Pregabain; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabain | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: Imipramine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipramine | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Imipramine plus pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Imipramine, pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine; Assigned to Arm(s): Imipramine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Imipramine, pregabalin; Assigned to Arm(s): Imipramine plus pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant
Brief Summary: This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy.


Options:
A: Arm Label: Tisagenlecleucel+Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab
B: Arm Label: Treatment (T cell therapy); Type: EXPERIMENTAL; Interventions: Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes | Intervention Type: BIOLOGICAL; Name: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes; Assigned to Arm(s): Treatment (T cell therapy)
C: Arm Label: Arm A - Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Arm B - JCAR017; Type: EXPERIMENTAL; Interventions: Genetic: JCAR017 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Arm A - Standard of Care (SOC) | Intervention Type: GENETIC; Name: JCAR017; Assigned to Arm(s): Arm B - JCAR017
D: Arm Label: Treatment (genetically modified T cell infusion); Type: EXPERIMENTAL; Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Procedure: autologous hematopoietic stem cell transplantation, Other: laboratory biomarker analysis | Intervention Type: BIOLOGICAL; Name: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Treatment (genetically modified T cell infusion) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (genetically modified T cell infusion)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone.
Brief Summary: The purpose of this study is to generate data to support the registration extension of IMOVAX Polio to be used in a sequential vaccination.

Primary objective:

* To demonstrate the non-inferiority of Inactivated Poliomyelitis Vaccine (IPV)-(Oral Poliomyelitis Vaccine) (OPV)-OPV (Sequential 1) and IPV-IPV-OPV (sequential 2) poliovirus vaccine administrations versus OPV-OPV-OPV (Reference) in terms of seroprotection rate 28 to 42 days after the third dose of the primary vaccination series.

Secondary objectives:

* To evaluate the safety profile of the investigational vaccines after each administration in each group.
* To describe the humoral immune response to poliovirus serotypes (types 1, 2 and 3) before the first dose and 28 to 42 days after the third primary series dose of vaccine in each group.
* To describe the persistence of antibodies against poliovirus serotypes (types 1, 2 and 3) after the third primary series dose administration, at 18 months of age in each group.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral polio vaccine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Oral polio vaccine; Assigned to Arm(s): A
B: Arm Label: POLIORIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): POLIORIX GROUP
C: Arm Label: Group A (Sequential 1): IPV-OPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio | Arm Label: Group B (Sequential 2): IPV-IPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio | Arm Label: Group C (Reference): OPV-OPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Live oral poliovirus type 1, 2 and 3 | Intervention Type: BIOLOGICAL; Name: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Assigned to Arm(s): Group A (Sequential 1): IPV-OPV-OPV | Intervention Type: BIOLOGICAL; Name: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Assigned to Arm(s): Group B (Sequential 2): IPV-IPV-OPV | Intervention Type: BIOLOGICAL; Name: Live oral poliovirus type 1, 2 and 3; Assigned to Arm(s): Group C (Reference): OPV-OPV-OPV
D: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REPLACE (Randomized Evaluation of Fibrinogen Versus Placebo in Complex Cardiovascular Surgery): a Prospective, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study for the Use of Fibrinogen Concentrate (Human) (FCH) in Complex Cardiovascular Surgery
Brief Summary: The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce the amount of donor blood products needed during complex cardiovascular surgery, and that it is safe and well tolerated. Subjects in this study will get either a FCH or placebo infusion during surgery. This will be in addition to the standard treatment, which is donor blood or blood products. Placebo does not contain any effective medicine.

The study is randomised. This means that the likelihood that subjects will get FCH or placebo is 50%. To make the comparison between FCH and placebo as fair as possible, the study is "double blind". This means that neither the subjects nor the study doctor will know if FCH or placebo is administered. If necessary, the study doctor can find out which treatment the subjects are receiving.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fibrinogen | Arm Label: Study drug; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen | Intervention Type: DRUG; Name: Fibrinogen; Assigned to Arm(s): Placebo, Study drug
B: Arm Label: Coagulation factor concentrates; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate | Arm Label: Fresh Frozen Plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh Frozen Plasma blood type 0, A, B and AB | Intervention Type: DRUG; Name: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate; Assigned to Arm(s): Coagulation factor concentrates | Intervention Type: DRUG; Name: Fresh Frozen Plasma blood type 0, A, B and AB; Assigned to Arm(s): Fresh Frozen Plasma
C: Arm Label: Fibrinogen Concentrate (Human); Type: EXPERIMENTAL; Interventions: Biological: Fibrinogen Concentrate (Human) (FCH) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Fibrinogen Concentrate (Human) (FCH); Assigned to Arm(s): Fibrinogen Concentrate (Human) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human albumin (Placebo) | Arm Label: Haemocomplettan® P; Type: EXPERIMENTAL; Interventions: Drug: Haemocomplettan® P | Intervention Type: DRUG; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: DRUG; Name: Human albumin (Placebo); Assigned to Arm(s): Albumin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Open Label Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease
Brief Summary: The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG) in reducing serum phosphorus in subjects with chronic kidney disease.


Options:
A: Arm Label: Renvela; Type: EXPERIMENTAL; Interventions: Drug: Renvela | Arm Label: Etalpha; Type: EXPERIMENTAL; Interventions: Drug: Etalpha | Intervention Type: DRUG; Name: Renvela; Assigned to Arm(s): Renvela | Intervention Type: DRUG; Name: Etalpha; Assigned to Arm(s): Etalpha
B: Arm Label: K2CG chewing gum (20 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (20mg chitosan) | Arm Label: K2CG chewing gum (60 mg chitosan); Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum (60mg chitosan) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: K2CG chewing gum (20mg chitosan); Assigned to Arm(s): K2CG chewing gum (20 mg chitosan) | Intervention Type: OTHER; Name: K2CG chewing gum (60mg chitosan); Assigned to Arm(s): K2CG chewing gum (60 mg chitosan)
C: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride
D: Arm Label: Sevelamer Carbonate; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer Carbonate | Arm Label: calcium carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcium carbonate | Intervention Type: DRUG; Name: Sevelamer Carbonate; Assigned to Arm(s): Sevelamer Carbonate | Intervention Type: DRUG; Name: calcium carbonate; Assigned to Arm(s): calcium carbonate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safe and Effective Vitamin D Supplementation in HIV
Brief Summary: The purpose of this study is to evaluate safety and efficacy of vitamin D supplementation in children, adolescents and young adults with Human Immunodeficiency Virus and acquired immunodeficiency syndrome (HIV/AIDS). The study is a 12-month randomized, double blind, placebo-controlled study of vitamin D3 (vit D) supplementation using 7000IU/day based on evidence from the Vit D Dose Finding Study-IRB 09-007332.


Options:
A: Arm Label: A: tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: B: tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: C: no tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: D: no tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D supplement; Assigned to Arm(s): A: tenofovir/vitamin D, C: no tenofovir/vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B: tenofovir/placebo, D: no tenofovir/placebo
B: Arm Label: 4000 IU/d of D3 by mouth for 12 weeks; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 4000 IU/d D3 over 12 weeks | Arm Label: 7000IU/d of D3 by mouth for 12 weeks; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 7000 IU/d D3 over 12 weeks | Intervention Type: DIETARY_SUPPLEMENT; Name: 4000 IU/d D3 over 12 weeks; Assigned to Arm(s): 4000 IU/d of D3 by mouth for 12 weeks | Intervention Type: DIETARY_SUPPLEMENT; Name: 7000 IU/d D3 over 12 weeks; Assigned to Arm(s): 7000IU/d of D3 by mouth for 12 weeks
C: Arm Label: 7000IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): 7000IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Multivitamins (B,C,E); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Multivitamin supplements B,C and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplements B,C and E; Assigned to Arm(s): Multivitamins (B,C,E), Placebo

Answer: C